Executive

Essam Enan, Ph.D. - Chief Scientific Officer

Essam Enan, Ph.D. is a renowned biochemist and toxicologist, and is the inventor of TyraTech's proprietary screening and product. Most recently, Dr Enan has been a research professor at Vanderbilt, and while there he developed the intellectual property that forms the technical foundation for the Company. Dr. Enan manages all technology at TyraTech, including overseeing the Company's laboratories at TyraTech and Vanderbilt University.

Prior to Vanderbilt, Dr. Enan was a faculty member at the University of California, Davis, Institute of Toxicology and Environmental Health. Dr. Enan has devoted the last 32 years to teaching and innovative research, with hundreds of scientific publications in peer-reviewed journals and many patents to his credit. He has become renown in the field of insect repellency, and has a deep knowledge of G-protein coupled receptors, as well as the chemistry and utility of plant essential oils as they apply to the development of molecularly targeted insecticides.

Peter Porpiglia, Ph.D. - Vice President Development

In his more than 20 years in agronomic and horticultural production, Dr. Porpiglia has specialized in leading the design and testing of diverse biotechnologies in the United States and other countries worldwide. Prior to joining TyraTech, Dr. Porpiglia was Vice President of Research and Development for Kumiai America, and Director of Research and Development for the Ciba-Geigy and Novartis Corporations; forerunners to what is now the global agribusiness, Syngenta AG. At TyraTech, Dr. Porpiglia is leading the development of a line of patented commercial, consumer, and agricultural products as well as exploring novel areas to expand TyraTech's product line.

Shayne M. Wetherall - Vice President Commercial Operations

Mr. Wetherall has extensive executive experience building and leading emerging growth and technology companies. Prior to joining TyraTech, Mr. Wetherall was the Managing Partner at Enright Partners, a boutique investment banking firm advising technology companies in the areas of M&A, corporate finance, turnarounds, and strategy. Prior to Enright, Mr. Wetherall served as interim CEO of enterprise software developer, Ideal Systems and defense technology integrator, EMX. Prior, he led M&A advisory firm, Advisory & Intermediary Services, and served in the US Navy SEAL teams.

Mr. Wetherall is a member of the Association for Corporate Growth and the UDT-SEAL Association and holds a Bachelor's degree from Marshall University.

Alan Reade - Executive Chairman

Mr Reade was appointed on May 25, 2007. He is owner of Global Strategy Expression Limited, a consulting and advisory services business in the life sciences industry. From 2000 until his retirement in 2005, he served as executive chairman of Merial Limited, a leading animal health company and joint venture between Merck & Co. Inc. and Sanofi- Aventis. Earlier in his career he was head of global integration at Aventis, where he was in charge of merger integration, and Chief Executive Officer and member of the Global at Rhone-Poulenc Inc. He previously has been a director of Sygen International and IFAH, a global animal health association.